Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection
about
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionChimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 virusesMicroneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunityProgress in developing virus-like particle influenza vaccines.New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges.Microneedle and mucosal delivery of influenza vaccines.Virus-like particles as universal influenza vaccinesIntranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virusHepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responsesThe B7-1 cytoplasmic tail enhances intracellular transport and mammalian cell surface display of chimeric proteins in the absence of a linear ER export motif.Incorporation of membrane-anchored flagellin or Escherichia coli heat-labile enterotoxin B subunit enhances the immunogenicity of rabies virus-like particles in mice and dogs.Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors.Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs.Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligandOral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 virusesVirus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice.Mucosal adjuvants for influenza virus-like particle vaccine.Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines.Influenza virosomes as vaccine adjuvant and carrier system.Intranasal formulations: promising strategy to deliver vaccines.Advances and challenges in the development and production of effective plant-based influenza vaccines.Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine.Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.Mucosal vaccine delivery: Current state and a pediatric perspectivePreparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein.Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro.Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.Prospects of HA-based universal influenza vaccine.NLRC4 Inflammasome-Driven Immunogenicity of a Recombinant MVA Mucosal Vaccine Encoding Flagellin.Intranasal immunization with a peptide conjugated to Salmonella flagellin induces both systemic and mucosal peptide-specific antibody responses in mice.Sequential Immunizations with heterosubtypic virus-like particles elicit cross protection against divergent influenza A viruses in mice.Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes.Influence of the Linking Order of Fragments of HA2 and M2e of the influenza A Virus to Flagellin on the Properties of Recombinant Proteins.Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine
P2860
Q26775082-F8CDAC3A-1CAB-41BC-8329-352E2154D591Q28365124-7805B411-FD75-45D6-8C47-97227D9A16FEQ30357830-97F3F707-B787-4671-92CD-DA1F0B7B0C2DQ30386640-9168C817-417A-4CA2-9615-E1719D4C5EC2Q30407424-C3408F28-7CAE-4E66-A7D1-78C287C63DE0Q30418015-B0560162-BC9D-4B92-9A03-A645C7B2C643Q30421558-60377DE2-DA87-4905-A900-9E6BCB9ADF79Q30431867-F8E0CBE1-ACDB-47B1-B901-9FDBC4E8B2BFQ34455275-40800405-6448-4235-BF38-4E8EA1679748Q35000777-A658CF1C-3147-456A-BDBF-3338E97F3F2DQ35140889-E60E7C71-AFB8-4FEE-8420-702B8510C1C7Q35209148-6FA44FC2-6193-4804-BD56-38A0628D62B7Q35645628-0DF0DD19-A441-4D0D-8F06-E9E191F409B4Q35824686-46275120-9E08-4A2E-9177-02BDF7F959A6Q36017750-85778C0D-16CA-49CA-960E-02B2433F4C1BQ36154739-3A6C2F4B-38C3-4638-9070-3C2C8D8D139EQ36640081-57F45E49-9474-491D-9387-085CE0ABF189Q36846046-9A3FAEEA-941B-4E78-ABA1-44998C1EEF2FQ37018558-8CC8ACB0-04F6-4F50-AEA8-F78B312CFEACQ37101184-2D2E9AA4-C58F-4EF3-8C0B-4BDDE6ACF5BFQ37404044-E56E1E3C-E654-4CEB-8075-F872C87ABF79Q37627859-EC8C26D5-D08B-4962-8C24-9FE8FF2B0AACQ38124062-3B01E70F-8ECA-4034-A4CA-356122EFCF1CQ38223050-E245DDCF-C882-48CA-9F56-862AA43E10A7Q38285425-8411DD8F-0109-4EBE-A26F-B65B5AD9A923Q38418305-B0A01716-5205-495D-81BC-D68FF316CD82Q38554795-85CC318D-A3B1-48C1-ABD1-A44D35D276DDQ38727453-42E4287D-710F-476F-B574-76D31016CB63Q38822536-E9D14F16-6E8F-4A42-AACA-5AE7A52FDF8DQ40121454-0EA00937-AA1E-4914-A5E5-8200FA71B22DQ40157020-E2131516-E855-4142-B14C-86E11F36F319Q41416400-6AEE69CD-733F-49F6-8881-7FE8CF3D280EQ49702857-E288A986-EDDA-4080-A4F9-F7844FA43D2BQ49964472-111974AC-DFA3-4364-8273-BE2376887646Q52653233-4B94CD0C-53E2-4756-84FF-6F293A7418E6Q54239201-48B26BFE-5D4E-42BC-814E-F5DC6D264648Q55096280-7C8C0308-637E-4577-9BFC-A9797C48D81CQ56989454-45456D27-6C14-435A-9C28-C913FA9B09B5
P2860
Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Intranasal immunization with i ...... rong heterosubtypic protection
@ast
Intranasal immunization with i ...... rong heterosubtypic protection
@en
Intranasal immunization with i ...... rong heterosubtypic protection
@nl
type
label
Intranasal immunization with i ...... rong heterosubtypic protection
@ast
Intranasal immunization with i ...... rong heterosubtypic protection
@en
Intranasal immunization with i ...... rong heterosubtypic protection
@nl
prefLabel
Intranasal immunization with i ...... rong heterosubtypic protection
@ast
Intranasal immunization with i ...... rong heterosubtypic protection
@en
Intranasal immunization with i ...... rong heterosubtypic protection
@nl
P2093
P2860
P3181
P1433
P1476
Intranasal immunization with i ...... rong heterosubtypic protection
@en
P2093
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0013972
P407
P577
2010-11-29T00:00:00Z